Centrum Medycyny Oddechowej Mroz Sp. j.
- Address
- lock Available on a paid plan
Asthma and Severe Asthma
The centre focuses on asthma across its severity spectrum, aiming to test innovative therapies that lower exacerbation risk and improve lung function.
- Evaluation of oral agents for moderate‑to‑severe uncontrolled asthma
- Comparison of inhaled triple therapy versus dual bronchodilator regimens in severe asthma
- Assessment of biologics targeting eosinophilic pathways to reduce severe attacks
- Long‑term safety monitoring of novel monoclonal antibodies in high‑risk asthma patients
These studies, conducted at the Bialystok facility, support patients seeking advanced treatment options for difficult‑to‑control asthma.
COPD and Exacerbation Management
Research at the site addresses chronic obstructive pulmonary disease by evaluating new drug combinations and anti‑inflammatory strategies to lessen exacerbations.
- Triple inhaler therapy versus dual bronchodilator outcomes in chronic obstructive pulmonary disease
- IL‑33 inhibition with itepekimab to reduce COPD flare‑ups
- Add‑on inhaled corticosteroid/LABA/LAMA regimens for former smokers with moderate‑to‑severe chronic obstructive pulmonary disease
- Evaluation of novel molecules such as AZD6793 for exacerbation rate reduction in chronic obstructive pulmonary disease
The programme includes long‑term safety extensions, providing valuable data for individuals living with chronic obstructive pulmonary disease.
Idiopathic Pulmonary Fibrosis
The centre investigates therapies aimed at slowing disease progression in patients with idiopathic pulmonary fibrosis.
- Antifibrotic agents assessed for preservation of lung volume in idiopathic pulmonary fibrosis
- Measurement of forced vital capacity decline to gauge treatment impact
- Safety and tolerability profiling of novel investigational compounds in idiopathic pulmonary fibrosis cohorts
Findings from these trials help refine therapeutic options for those diagnosed with idiopathic pulmonary fibrosis at the Bialystok clinic.
Bronchiectasis Research
Focused studies target non‑cystic fibrosis bronchiectasis, seeking to lessen infection‑driven worsening and improve quality of life.
- Anti‑IL‑33 monoclonal antibody (itepekimab) to lower exacerbation frequency in bronchiectasis
- Inhaled nitric oxide formulation (RESP30X) for patients with high‑titer pathogenic microbes
- Evaluation of novel antibiotics and adjunct therapies to manage chronic infections in bronchiectasis
The research supports patients with bronchiectasis by exploring treatments that address both inflammation and bacterial colonisation.
Pulmonary Sarcoidosis Studies
Clinical work at the centre includes trials for pulmonary sarcoidosis, aiming to assess disease‑modifying agents and monitor systemic involvement.
- Long‑term safety of monoclonal antibody XTMAB‑16 in pulmonary sarcoidosis with or without extra‑pulmonary manifestations
- Biomarker and imaging evaluation to track disease activity during treatment
- Comparative effectiveness of immunomodulatory therapies for organ‑specific outcomes
These efforts at Centrum Medycyny Oddechowej Mroz enhance therapeutic choices for individuals affected by pulmonary sarcoidosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 38 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1AstraZeneca AB3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medycyny Oddechowej Mroz Sp. j.
lock Showing 1 of 52 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 38 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol | 8 | Unknown | 2021-04-29 | 2025-11-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.